Systematic review finds ecnoglutide improves glycaemic control in adults with T2DM, suggesting strong therapeutic potential.
Ecnoglutide demonstrates robust efficacy in glycaemic control, weight reduction, and cardiometabolic parameters with an acceptable safety profile in adults with T2DM, supporting its therapeutic potential as a next-generation GLP-1 receptor agonist.
No takes yet. Share an insight, caveat, or question.
Kumar et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: